This study aims to evaluate the efficacy of Ex-one tablets, a two-drug fixed-dose combination of amlodipine and valsartan, or Ex-one Plus tablets, a three-drug fixed-dose combination of amlodipine, valsartan, and chlorthalidone, in patients with essential hypertension in a real-world setting, focusing on the proportion of patients who achieve blood pressure control rates. In addition, safety data will be collected and evaluated in a large patient population.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Aged 19 years or older
2. Patients for whom a decision has been made to administer the study medication for the treatment of essential hypertension in accordance with the approved prescribing information
3. Patients who voluntarily provide written informed consent
You may not be if
1. Patients for whom administration of the study medication is contraindicated according to the approved prescribing information
2. Patients whom the investigator considers medically unsuitable for participation in this study for reasons other than those specified above